Background: There is a strong relationship between hepatitis C virus (HCV) infection and the kidney. Approximately 10-16% of the patients with HCV infection develop renal disease, and the prevalence of HCV infection in patients with renal dysfunction is higher than that of the general population (9.5 vs. 1.6%). Moreover, HCV-positive patients on hemodialysis (HD) have higher mortality rates as compared to HCV-negative patients also on HD, not only due to liver-related complications but also owing to cardiovascular disease. Key Messages: In the interferon era, the treatment of HCV infection in patients on HD was hampered due to a significant number of treatment-related adverse events (predominately anemia and infectious complications). The development of direct-acting antivirals (DAAs) has revolutionized the field allowing viral eradication in these very sick patients. Two recently published clinical trials assessed the efficacy and safety of DAAs in patients with end-stage renal disease (ESRD). The combination of grazoprevir and elbasvir has been studied in the C-SURFER trial with 94% of the patients achieving sustained virological response (SVR). Adverse events were mild and only a small number of patients discontinued therapy early due to adverse events. The 3D regimen was evaluated in the RUBY-I trial. Here, a 90% SVR rate was achieved in 20 patients with ESRD, most of them on HD. Although sofosbuvir is eliminated by the kidney and its use in patients with glomerular filtration rate <30 mL/min is not recommended, real-life data have shown good results for this drug in terms of efficacy and safety. Conclusions: The use of DAAs has safely permitted the treatment of patients with renal dysfunction with excellent efficacy results.

Keywords:
End-stage renal disease, Hepatitis C, Direct-acting antivirals
1.
Goodkin DA, Bieber B, Gillespie B, Robinson BM, Jadoul M: Hepatitis C infection is very rarely treated among hemodialysis patients. Am J Nephrol 2013;38:405-412.
2.
Fabrizi F, Dixit V, Messa P: Impact of hepatitis C on survival in dialysis patients: a link with cardiovascular mortality? J Viral Hepat 2012;19:601-607.
3.
Dammacco F, Sansonno D: Therapy for hepatitis C virus-related cryoglobulinemic vasculitis. N Engl J Med 2013;369:1035-1045.
4.
El-Serag HB, Hampel H, Yeh C, Rabeneck L: Extrahepatic manifestations of hepatitis C among United States male veterans. Hepatology 2002;36:1439-1445.
5.
Tsui JI, Vittinghoff E, Shlipak MG, O'Hare AM: Relationship between hepatitis C and chronic kidney disease: results from the third national health and nutrition examination survey. J Am Soc Nephrol 2006;17:1168-1174.
6.
Tsui JI, Vittinghoff E, Shlipak MG, Bertenthal D, Inadomi J, Rodriguez RA, O'Hare AM: Association of hepatitis C seropositivity with increased risk for developing end-stage renal disease. Arch Intern Med 2007;167:1271-1276.
7.
Chen YC, Lin HY, Li CY, Lee MS, Su YC: A nationwide cohort study suggests that hepatitis C virus infection is associated with increased risk of chronic kidney disease. Kidney Int 2014;85:1200-1207.
8.
Park H, Adeyemi A, Henry L, Stepanova M, Younossi Z: A meta-analytic assessment of the risk of chronic kidney disease in patients with chronic hepatitis C virus infection. J Viral Hepat 2015;22:897-905.
9.
KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int Suppl 2013;3:1-149.
10.
European Association for Study of Liver: EASL recommendations on treatment of hepatitis C 2015. J Hepatol 2015;63:199-236.
11.
Schiavon LL, Schiavon JL, Filho RJ, Sampaio JP, Lanzoni VP, Silva AE, Ferraz ML: Simple blood tests as noninvasive markers of liver fibrosis in hemodialysis patients with chronic hepatitis C virus infection. Hepatology 2007;46:307-314.
12.
Liu CH, Liang CC, Huang KW, Liu CJ, Chen SI, Lin JW, Hung PH, Tsai HB, Lai MY, Chen PJ, Chen JH, Chen DS, Kao JH: Transient elastography to assess hepatic fibrosis in hemodialysis chronic hepatitis C patients. Clin J Am Soc Nephrol 2011;6:1057-1065.
13.
Khunpakdee N, Jayanama K, Kaewdoung P, Promson K, Rattanasiri S, Warodomwichit D, Kantachuvesiri S, Sobhonslidsuk A: Transient elastography in end-stage renal disease patients on hemodialysis: the effect of net fluid withdrawal. Blood Purif 2015;40:256-259.
14.
Varaut A, Fontaine H, Serpaggi J, Verkarre V, Vallet-Pichard A, Nalpas B, Imbertbismuth F, Lebray P, Pol S: Diagnostic accuracy of the fibrotest in hemodialysis and renal transplant patients with chronic hepatitis C virus. Transplantation 2005;80:1550-1555.
15.
Fabrizi F, Aghemo A, Messa P: Hepatitis C treatment in patients with kidney disease. Kidney Int 2013;84:874-879.
16.
Fabrizi F, Verdesca S, Messa P, Martin P: Hepatitis C virus infection increases the risk of developing chronic kidney disease: a systematic review and meta-analysis. Dig Dis Sci 2015;60:3801-3813.
17.
Bucci JR, Lentine KL, Agodoa LY, Peters TG, Schnitzler MA, Abbott KC: Outcomes associated with recipient and donor hepatitis C serology status after kidney transplantation in the united states: analysis of the USRDS/UNOS database. Clin Transpl 2004:51-61.
18.
Abbott KC, Lentine KL, Bucci JR, Agodoa LY, Peters TG, Schnitzler MA: The impact of transplantation with deceased donor hepatitis c-positive kidneys on survival in wait-listed long-term dialysis patients. Am J Transplant 2004;4:2032-2037.
19.
Bucci JR, Matsumoto CS, Swanson SJ, Agodoa LY, Holtzmuller KC, Peters TG, Abbott KC: Donor hepatitis C seropositivity: clinical correlates and effect on early graft and patient survival in adult cadaveric kidney transplantation. J Am Soc Nephrol 2002;13:2974-2982.
20.
Morales JM, Campistol JM, Dominguez-Gil B, Andres A, Esforzado N, Oppenheimer F, Castellano G, Fuertes A, Bruguera M, Praga M: Long-term experience with kidney transplantation from hepatitis C-positive donors into hepatitis c-positive recipients. Am J Transplant 2010;10:2453-2462.
21.
Bloom RD, Sayer G, Fa K, Constantinescu S, Abt P, Reddy KR: Outcome of hepatitis C virus-infected kidney transplant candidates who remain on the waiting list. Am J Transplant 2005;5:139-144.
22.
Kamar N, Marion O, Rostaing L, Cointault O, Ribes D, Lavayssiere L, Esposito L, Del Bello A, Metivier S, Barange K, Izopet J, Alric L: Efficacy and safety of sofosbuvir-based antiviral therapy to treat hepatitis C virus infection after kidney transplantation. Am J Transplant 2016;16:1474-1479.
23.
Sawinski D, Kaur N, Ajeti A, Trofe-Clark J, Lim M, Bleicher M, Goral S, Forde KA, Bloom RD: Successful treatment of hepatitis C in renal transplant recipients with direct-acting antiviral agents. Am J Transplant 2016;16:1588-1595.
24.
Lin MV, Sise ME, Pavlakis M, Amundsen BM, Chute D, Rutherford AE, Chung RT, Curry MP, Hanifi JM, Gabardi S, Chandraker A, Heher EC, Elias N, Riella LV: Efficacy and safety of direct acting antivirals in kidney transplant recipients with chronic hepatitis C virus infection. PLoS One 2016;11:e0158431.
25.
Colombo M, Aghemo A, Liu L, Hyland R, Yun C, Brainard D, McHutchinson J, Bourliere M, Peck-Radosavljevic M, Manns M, Pol S: Ledipasvir/sofosbuvir for 12 or 24 weeks is safe and effective in kidney transplant recipients with chronic genotype 1 or 4 HCV infection. J Hepatol 2016;64:S183.
26.
Sawinski D, Lee DH, Doyle AM, Blumberg EA: Successful posttransplant treatment of hepatitis C with ledipasvir-sofosbuvir in HIV+ kidney transplant recipients. Transplantation 2016, Epub ahead of print.
27.
Zeuzem S, Dusheiko GM, Salupere R, Mangia A, Flisiak R, Hyland RH, Illeperuma A, Svarovskaia E, Brainard DM, Symonds WT, Subramanian GM, McHutchison JG, Weiland O, Reesink HW, Ferenci P, Hezode C, Esteban R: Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014;370:1993-2001.
28.
Nelson DR, Cooper JN, Lalezari JP, Lawitz E, Pockros PJ, Gitlin N, Freilich BF, Younes ZH, Harlan W, Ghalib R, Oguchi G, Thuluvath PJ, Ortiz-Lasanta G, Rabinovitz M, Bernstein D, Bennett M, Hawkins T, Ravendhran N, Sheikh AM, Varunok P, Kowdley KV, Hennicken D, McPhee F, Rana K, Hughes EA: All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology 2015;61:1127-1135.
29.
Leroy V, Angus P, Bronowicki JP, Dore GJ, Hezode C, Pianko S, Pol S, Stuart K, Tse E, McPhee F, Bhore R, Jimenez-Exposito MJ, Thompson AJ: Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: a randomized phase III study (ALLY-3+). Hepatology 2016;63:1430-1441.
30.
Ladino M, Pedraza F, Roth D: Hepatitis c virus infection in chronic kidney disease. J Am Soc Nephrol 2016;27:2238-2246.
31.
Sawinski D, Bloom RD: Novel hepatitis C treatment and the impact on kidney transplantation. Transplantation 2015;99:2458-2466.
32.
Kirby BJ, Symonds WT, Kearney BP, Mathias AA: Pharmacokinetic, pharmacodynamic, and drug-interaction profile of the hepatitis C virus NS5B polymerase inhibitor sofosbuvir. Clin Pharmacokinet 2015;54:677-690.
33.
Desnoyer A, Pospai D, Le MP, Gervais A, Heurgue-Berlot A, Laradi A, Harent S, Pinto A, Salmon D, Hillaire S, Fontaine H, Zucman D, Simonpoli AM, Muret P, Larrouy L, Bernard Chabert B, Descamps D, Yazdanpanah Y, Peytavin G: Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C. J Hepatol 2016;65:40-47.
34.
Bhamidimarri KR, Czul F, Peyton A, Levy C, Hernandez M, Jeffers L, Roth D, Schiff E, OʼBrien C, Martin P: Safety, efficacy and tolerability of half-dose sofosbuvir plus simeprevir in treatment of hepatitis C in patients with end stage renal disease. J Hepatol 2015;63:763-765.
35.
Nazario HE, Ndungu M, Modi AA: Sofosbuvir and simeprevir in hepatitis c genotype 1-patients with end-stage renal disease on haemodialysis or GFR <30 ml/min. Liver Int 2016;36:798-801.
36.
Saxena V, Koraishy FM, Sise ME, Lim JK, Schmidt M, Chung RT, Liapakis A, Nelson DR, Fried MW, Terrault NA: Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function. Liver Int 2016;36:807-816.
37.
Beinhardt S, Al Zoairy R, Ferenci P, Kozbial K, Freissmuth C, Stern R, Stattermayer AF, Stauber R, Strasser M, Zoller H, Watschinger B, Schmidt A, Trauner M, Hofer H, Maieron A: Daa-based antiviral treatment of patients with chronic hepatitis C in the pre- and postkidney transplantation setting. Transpl Int 2016;29:999-1007.
38.
Cornpropst M, Denning J, Clemons D, et al: The effect of renal impairment and end stage renal disease on the single-dose pharmacokinetics of PSI-7977. J Hepatol 2012;56:S433.
39.
Khatri A, Dutta S, Marbury TC, Preston RA, Rodrigues L Jr, Wang H, Awni WM, Menon RM: Pharmacokinetics and tolerability of anti-hepatitis C virus treatment with ombitasvir, paritaprevir, ritonavir, with or without dasabuvir, in subjects with renal impairment. Clin Pharmacokinet 2017;56:153-163.
40.
Garimella T, Wang R, Luo WL, Hwang C, Sherman D, Kandoussi H, Marbury TC, Alcorn H, Bertz R, Bifano M: Single-dose pharmacokinetics and safety of daclatasvir in subjects with renal function impairment. Antivir Ther 2015;20:535-543.
41.
Mogalian E, Mathias AA, Yang JC, Pang PS, Moorehead L, Hernandez M, Lasseter KC, Ries D, Robson RA, Klein G: The pharmacokinetics of ledipasvir, an HCV specific NS5A inhibitor, in HCV-uninfected subjects with severe renal impairment. Hepatology 2014;60.
42.
Yeh WW, Caro L, Guo Z, Pung Feng H, Davis HU, Kozisek M, Stypinski D, Feng C, Mitchell C, Gillespie A, Ichhpurani N, Marshall WL, Lasseter KC, Marbury TC, Butterton JR: Pharmacokinetics of co-administered HCV protease inhibitor mk-5172 and NS5A inhibitor mk-8742 in volunteers with end-stage renal disease on hemodialysis or severe renal impairment not on hemodialysis. Hepatology 2014;60:1137A.
44.
Ouwerkerk-Mahadevan S, Beumont-Mauviel M, Mortier S, Peeters M, Verloes R, Truyers C, Mannens G, Wynant I, Simion A: Evaluation of the pharmacokinetics and renal excretion of simeprevir in subjects with renal impairment. Drugs R D 2015;15:261-270.
45.
Roth D, Nelson DR, Bruchfeld A, Liapakis A, Silva M, Monsour H Jr, Martin P, Pol S, Londono MC, Hassanein T, Zamor PJ, Zuckerman E, Wan S, Jackson B, Nguyen BY, Robertson M, Barr E, Wahl J, Greaves W: Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet 2015;386:1537-1545.
46.
Pockros PJ, Reddy KR, Mantry PS, Cohen E, Bennett M, Sulkowski MS, Bernstein DE, Cohen DE, Shulman NS, Wang D, Khatri A, Abunimeh M, Podsadecki T, Lawitz E: Efficacy of direct-acting antiviral combination for patients with hepatitis c virus genotype 1 infection and severe renal impairment or end-stage renal disease. Gastroenterology 2016;150:1590-1598.
47.
Gane E, Robson R, Bonacini M, Maliakkal B, Kirby B, Liu L, Sajwani K, Stamm L, Brainard D, McHutchison J, Stedman C, Lawitz E: Safety, antiviral efficacy, and pharmacokinetics of sofosbuvir in patients with severe renal impairment. Hepatology 2014;60:667A.
48.
Martin P, Gane E, Ortiz-Lasanta G, Liu L, Sajwani K, Kirby B, Stamm L, Brainard D, McHutchison J, Lawitz E, Gordon E, Robson R: Safety and efficacy of treatment with daily sofosbuvir 400 mg + ribavirin 200 mg for 24 weeks in genotype 1 or 3 HCV-infected patients with severe renal impairment. Hepatology 2015;62:765A.
49.
Perumpail RB, Wong RJ, Ha LD, Pham EA, Wang U, Luong H, Kumari R, Daugherty TJ, Higgins JP, Younossi ZM, Kim WR, Glenn JS, Ahmed A: Sofosbuvir and simeprevir combination therapy in the setting of liver transplantation and hemodialysis. Transpl Infect Dis 2015;17:275-278.
50.
Hundemer GL, Sise ME, Wisocky J, Ufere N, Friedman LS, Corey KE, Chung RT: Use of sofosbuvir-based direct-acting antiviral therapy for hepatitis c viral infection in patients with severe renal insufficiency. Infect Dis (Lond) 2015;47:924-929.
51.
Gane E, Sola R, Cohen E, Roberts SK, George J, Skoien R, Riordan S, Mobashery N, Abunimeh M, Cohen D, Agarwal K: RUBY-II: Efficacy and Safety of a Ribavirin-Free Ombitasvir/Paritaprevir/Ritonavir ± Dasabuvir Regimen in Patients With Severe Renal Impairment or End-Stage Renal Disease and HCV Genotype 1a or 4 Infection. Hepatology 2016;64(suppl 1):470A.
52.
Gane E, Lawitz E, Pugatch D, Papatheodoridis G, Bräu N, Brown A, Pol S, Leroy V, Persico M, Moreno C, Colombo M, Yoshida E, Nelson D, Lei Y, Kosloski M, Mensa F: EXPEDITION-4: Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Patients With Renal Impairment and Chronic Hepatitis C Virus Genotype 1-6 Infection. Hepatology 2016;64(suppl 1):1125A.
53.
Dumortier J, Bailly F, Pageaux GP, Vallet-Pichard A, Radenne S, Habersetzer F, Gagnieu MC, Grangé JD, Minello A, Guillaud O, Kamar N, Alric L, Leroy V: Sofosbuvir-based antiviral therapy in hepatitis C virus patients with severe renal failure. Nephrol Dial Transplant 2016;pii:gfw348 [Epub ahead of print].
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.